Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
STTK
Shattuck Labs, Inc.
Strategic focus on inflammatory/immune diseases (IBD) positions the company in Immunology Therapeutics.
|
$95.32M |
$1.99
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$94.79M |
$1.52
-4.69%
|
|
CSBR
Champions Oncology, Inc.
Company provides outsourced drug development and preclinical/clinical research services to biopharma (CRO-style).
|
$93.68M |
$6.75
-0.74%
|
|
INVE
Identiv, Inc.
Healthcare-focused applications (biometric sensing, device authentication) intersect with medical device/biometrics themes.
|
$93.05M |
$3.85
-2.41%
|
|
NNBR
NN, Inc.
Precision medical device components manufacturing, including implant-related parts (Medical Device Components).
|
$93.05M |
$1.81
-2.16%
|
|
STRO
Sutro Biopharma, Inc.
Directly represents Sutro's core assets: Antibody-Drug Conjugates (ADC) programs using the XpressCF+ platform.
|
$92.91M |
$1.06
-3.18%
|
|
LFVN
LifeVantage Corporation
LoveBiome's microbiome/gut-health focus expands into digestive-health supplement opportunities.
|
$92.40M |
$7.43
+1.23%
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK AB-101 is an allogeneic NK cell therapy platform, constituting Artiva's core product line.
|
$91.85M |
$3.83
+1.59%
|
|
COSG
Cosmos Group Holdings Inc.
Cana Laboratories' facility upgrades and a 5-year Pharmex contract manufacturing agreement indicate COSG's direct contract manufacturing service in pharma.
|
$91.72M |
$0.02
|
|
INO
Inovio Pharmaceuticals, Inc.
INO's core DNA medicines platform and lead candidate INO-3107 are gene therapy products based on DNA plasmids delivered via CELLECTRA; maps to gene therapy.
|
$91.69M |
$2.50
-0.20%
|
|
CNTB
Connect Biopharma Holdings Limited
Lead asset CBP-201 (rademikibart) is a monoclonal antibody targeting IL-4Rα, directly fitting Monoclonal Antibody Therapeutics.
|
$91.68M |
$1.67
+0.91%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is Alpha Cognition's lead therapeutic targeting Alzheimer's disease.
|
$91.31M |
$5.89
+3.42%
|
|
LHSW
Lianhe Sowell International Group Ltd Ordinary Shares
Exploration into medical applications via machine vision implies Medical Devices & Biometrics relevance.
|
$91.00M |
$1.75
|
|
GOCO
GoHealth, Inc.
GoHealth's core offering is health insurance enrollment and management for Medicare plans.
|
$90.68M |
$3.74
-2.09%
|
|
MGX
Metagenomi, Inc. Common Stock
MGX's core platform is gene therapy/gene editing tools enabling therapeutic gene modification, including in vivo MGX-1.00 programs.
|
$90.46M |
$2.37
-2.27%
|
|
ADVM
Adverum Biotechnologies, Inc.
Lead program Ixo-vec is a gene therapy for an ocular indication, placing Adverum in the Biotech - Gene Therapy category.
|
$89.62M |
$4.30
+0.35%
|
|
HYPR
Hyperfine, Inc.
Hyperfine's Swoop portable MRI is a medical imaging device, directly fitting the Medical Imaging category.
|
$87.96M |
$1.08
-4.42%
|
|
EUDA
EUDA Health Holdings Limited
EUDA's core biotech activity is a stem cell platform and cell therapy development using iPSCs.
|
$84.71M |
$2.21
-6.75%
|
|
ONCY
Oncolytics Biotech Inc.
Pelareorep is an oncolytic virus immunotherapy developed by Oncolytics Biotech, placing the company in Biotech - Oncology.
|
$84.01M |
$0.97
-10.98%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX Oncology explicitly focuses on cancer therapies (immuno-oncology), placing it under Biotech - Oncology.
|
$83.91M |
$1.58
+0.64%
|
|
BYSI
BeyondSpring Inc.
BeyondSpring develops oncology therapeutics (Plinabulin) with a novel SIMBA mechanism, directly addressing cancer and CIN.
|
$83.45M |
$2.00
-3.62%
|
|
ATRA
Atara Biotherapeutics, Inc.
Atara focuses on tab-cel (Ebvallo), an allogeneic T-cell therapy.
|
$82.57M |
$13.49
-2.60%
|
|
DTIL
Precision BioSciences, Inc.
ARCUS is Precision BioSciences' in vivo gene editing platform and the lead programs PBGENE-HBV and PBGENE-DMD are built on this technology for therapeutic gene edits.
|
$81.61M |
$7.26
-1.29%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$81.26M |
$1.28
-6.88%
|
|
AMWL
American Well Corporation
Amwell uses Carepoint and related hardware as part of its care-delivery ecosystem, aligning with medical devices/biometrics.
|
$80.47M |
$5.13
+0.79%
|
|
CAMP
CAMP4 Therapeutics Corporation
Direct product category: oligonucleotide therapeutics (RNA Actuating Platform) using ASOs to upregulate gene expression.
|
$79.43M |
$3.95
+0.25%
|
|
ADAG
Adagene Inc.
Core focus on monoclonal antibody therapeutics (ADG126 and related SAFEbody-based antibodies).
|
$79.24M |
$1.71
-4.47%
|
|
RPTX
Repare Therapeutics Inc.
Core company focus is oncology therapeutics with a synthetic lethality approach (Biotech - Oncology).
|
$78.92M |
$1.82
-1.09%
|
|
ATYR
aTyr Pharma, Inc.
Efzofitimod is a biologic immunomodulator addressing inflammation in ILD, aligning with Immunology Therapeutics.
|
$78.39M |
$0.84
-4.35%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$77.55M |
$11.78
-0.04%
|
|
MBOT
Microbot Medical Inc.
LIBERTY functions as a vascular/interventional device for endovascular surgery, aligning with Vascular Intervention Devices.
|
$77.12M |
$2.06
-3.07%
|
|
CRDL
Cardiol Therapeutics Inc.
Cardiol Therapeutics' lead drug is a cardiovascular therapy targeting heart disease.
|
$76.87M |
$1.07
-1.83%
|
Showing page 26 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
